PELL Bio-Med Technology Co. Ltd. (6949.TW)
TWD 83.5
(0.6%)
TWD 83.5
(0.6%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 18.03 Million | 17.15 Million | 13.97 Million |
| Cost of Revenue | 44.17 Million | 59.45 Million | 48.5 Million |
| Gross Profit | -26.14 Million | -42.29 Million | -34.53 Million |
| Operating Expenses | 385.1 Million | 193.81 Million | 161.43 Million |
| Selling, General and Administrative Expenses | 145.49 Million | 51.45 Million | 24.71 Million |
| Research and Development Expenses | 239.61 Million | 142.36 Million | 136.71 Million |
| Other Expenses | - | 3.92 Million | 8.26 Million |
| Cost and Expenses | 429.27 Million | 253.26 Million | 209.93 Million |
| Operating Income | -411.24 Million | -236.1 Million | -195.96 Million |
| Interest Expense | 2.55 Million | 1.36 Million | 1.51 Million |
| Income Tax Expense | 2000.00 | -1.14 Million | -14 Thousand |
| Earnings before Tax | -401.23 Million | -231.27 Million | -188.97 Million |
| Net Income | -398.75 Million | -230.13 Million | -188.95 Million |
| Earnings Per Share Basic | -8.62 | -5.87 | -5.68 |
| Earnings Per Share Diluted | -8.62 | -5.87 | -5.68 |
| Weighted Average Shares Outstanding | 46.25 Million | 39.22 Million | 33.27 Million |
| Weighted Average Shares Outstanding (Diluted) | 46.25 Million | 39.22 Million | 33.27 Million |
| Gross Margin | -1.45 | -2.47 | -2.47 |
| EBIT Margin | -19.59 | -11.95 | -11.86 |
| Profit Margin | -22.11 | -13.41 | -13.52 |
| EBITDA | -353.17 Million | -198.87 Million | -157.29 Million |
| Earnings Before Tax Margin | -22.81 | -13.76 | -14.02 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 5.01 Million | 4.99 Million | 3.41 Million | 18.03 Million | 4.55 Million | 4.99 Million |
| Cost of Revenue | 13.96 Million | 19.75 Million | 7.1 Million | 89.78 Million | 15.18 Million | 26.49 Million |
| Gross Profit | -8.94 Million | -14.75 Million | -3.69 Million | -71.75 Million | -10.62 Million | -21.5 Million |
| Operating Expenses | 102.56 Million | 74.1 Million | 99.82 Million | 339.49 Million | 110.05 Million | 105.14 Million |
| Selling, General and Administrative Expenses | 27.9 Million | 55.63 Million | 129.54 Million | - | 6.25 Million | 32.25 Million |
| Research and Development Expenses | 74.66 Million | 49.87 Million | 64.65 Million | - | 66.8 Million | 72.88 Million |
| Other Expenses | 4.63 Million | 31.39 Million | 2.54 Million | 4.82 Million | 153 Thousand | 2.08 Million |
| Cost and Expenses | 116.52 Million | 93.86 Million | 106.93 Million | 429.27 Million | 125.23 Million | 131.63 Million |
| Operating Income | -111.51 Million | -88.86 Million | -98.56 Million | -411.24 Million | -120.67 Million | -126.64 Million |
| Interest Expense | 552 Thousand | 576 Thousand | 600 Thousand | 2.55 Million | 625 Thousand | 650 Thousand |
| Income Tax Expense | -1.33 Million | -658 Thousand | -2.48 Million | 2000.00 | - | 2000.00 |
| Earnings before Tax | -102.87 Million | -85.95 Million | -99.16 Million | -401.34 Million | -119.01 Million | -123.24 Million |
| Net Income | -101.54 Million | -85.29 Million | -96.68 Million | -398.75 Million | -119.01 Million | -122.62 Million |
| Earnings Per Share Basic | -1.78 | -1.56 | -1.89 | - | -2.49 | -2.75 |
| Earnings Per Share Diluted | -1.78 | -1.56 | -1.89 | - | -2.49 | -2.75 |
| Weighted Average Shares Outstanding | 57.11 Million | 54.85 Million | 51.18 Million | 46.25 Million | 47.88 Million | 44.57 Million |
| Weighted Average Shares Outstanding (Diluted) | 57.11 Million | 54.85 Million | 51.18 Million | 46.25 Million | 47.88 Million | 44.57 Million |
| Gross Margin | -1.78 | -2.95 | -1.08 | -3.98 | -2.33 | -4.31 |
| EBIT Margin | -19.90 | -15.44 | -25.51 | - | -25.98 | -23.07 |
| Profit Margin | -20.25 | -17.06 | -28.28 | -22.11 | -26.12 | -24.57 |
| EBITDA | -99.75 Million | -77.18 Million | -87.22 Million | - | -118.39 Million | -115.11 Million |
| Earnings Before Tax Margin | -22.24 | -17.78 | -28.83 | -22.81 | -26.48 | -25.37 |
HUG
0RP4
HPGLY
2127
JMART-R
PR1